Company: XERI
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001477932-25-008494
Chunk: 42

Company: XERIANT, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Part I, Item 1
Chunk 42
---
  24,912   56,445 Professional fees  83,997   63,806 Research and development expense  53,966   26,561 Total operating expenses  304,075   358,795          Loss from operations  (304,075)  (358,795)         Other expenses:        Amortization of debt discount  (44,031)  (16,802)Interest expense  (44,783)  (61,617)Gain on extinguishment of debt  2,743,546   64,992 Total other income (expense)  2,654,732   (13,427)         Net income (loss) before income tax expense  2,350,657   (372,222)         Income tax expense  124,585   -          Net income (loss)  2,226,072   (372,222)         Less net loss attributable to noncontrolling interest  -   (7,376)         Net income (loss) attributable to common stockholders $2,226,072  $(364,846)         Basic and diluted earnings per share on net income (loss)        Basic $0.00  $(0.00)Diluted $0.00  $(0.00)         Weighted average number of common shares outstanding        Basic  716,715,546   547,575,614 Diluted  2,367,087,385   547,575,614 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 F-3Table of Contents

XERIANT, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025

UNAUDITED

  Series A Preferred Stock  Series B Preferred Stock  Common Stock  Common stock to be  Additional Paid in  Accumulated  Non-Controlling      Shares  Amount  Shares  Amount  Shares  Amount  issued  Capital  Deficit  Interest  Total Balance June 30, 2025